Regan Andrew Converts $195K Fee into 1.35 M CDT Equity Shares Amid 95% Stock Decline

Insider Activity Highlights for CDT Equity Inc.

Recent Transaction Impact On 22 October 2026, CEO Regan Andrew purchased 1,347,616 shares of CDT Equity’s common stock as part of a one‑time evaluation agreement with Manoira Corporation. The transaction converted a $195,000 fee into equity at a price of $0.1447 per share, giving Andrew a post‑transaction holding of 1,347,619 shares. While the nominal dollar amount is modest relative to the company’s market cap of $146 190, the deal signals confidence from a key stakeholder in the firm’s strategic direction. The conversion of a cash fee into stock is a common mechanism for aligning partner incentives, but it also increases the insider’s voting power at a time when the company’s share price remains highly volatile.

Implications for Investors and Future Outlook The purchase follows a series of aggressive buying and selling by Andrew over the past year, including the recent conversion of $65,000 of severance into 499,616 shares on 23 October 2026. This pattern of alternating buy‑sell activity suggests a liquidity‑management strategy rather than a long‑term bet on the stock’s price appreciation. Investors should note that the company’s stock has experienced a staggering 95.79 % decline over the past month and an 100 % drop over the year, with a 52‑week low of $0.09. The insider’s continued investment amidst these declines may be interpreted as a “buy‑the‑dip” stance, but it could also reflect a defensive position in anticipation of further regulatory or operational hurdles. Market participants will likely scrutinize future earnings reports and pipeline updates to gauge whether the insider’s confidence translates into tangible upside.

Regan Andrew: A Transactional Profile Andrew’s historical filings reveal a highly active insider who has traded both common stock and pre‑funded warrants in large volumes. From August 2026 back to December 2025, he has executed at least six large purchases and multiple sales totaling over 5 million shares. His most frequent activity involves pre‑funded warrants—often buying and selling them in bulk—suggesting a strategy focused on leveraging warrant upside while mitigating dilution. His holdings, however, remain relatively modest in dollar terms; the latest holding of 217,461 shares represents less than 0.2 % of the outstanding shares, given the company’s tiny market cap. Nonetheless, his repeated conversions of severance and fee payments into equity underscore a willingness to lock in ownership even in a high‑volatility environment.

Key Takeaways for Professionals

• The insider’s recent purchase is part of a broader pattern of liquidity‑driven transactions, not necessarily a bullish endorsement.
• The company’s financials and share price volatility remain a concern; investors should monitor upcoming clinical milestones and regulatory filings for potential catalysts.
• Regan Andrew’s history of warrant activity indicates a sophisticated understanding of equity instruments, which may bode well for strategic decision‑making but also introduces complexities for governance and dilution considerations.

Financial professionals should weigh the insider’s actions against the backdrop of CDT Equity’s precarious market position, remaining cautious yet open to any forthcoming developments that could alter the company’s trajectory.